Aurobindo Pharma Limited has informed the Exchange regarding a press release dated February 12, 2024, titled "Aurobindo Pharma receives USFDA Approval for Deflazacort Tablets, 6 mg, 18 mg, 30 mg, and 36 mg".
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated February 12, 2024, titled "Aurobindo Pharma receives USFDA Approval for Deflazacort Tablets, 6 mg, 18 mg, 30 mg, and 36 mg".